tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Maxwell Skor, 6 are a BUY (75%), 2 are a HOLD (25%).
Analyst Maxwell Skor, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 66.67% that have a potential upside of 33.51% achieved within 120 days.
Maxwell Skor’s has documented 16 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CYTK, Cytokinetics at 23-Dec-2025.
Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for INSM (INSMED) at 8/20/2025. The price target of $144 was fulfilled within 13 days with a profit of $14.55 (11.24%) receiving and performance score of 8.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Apr-2025
$280
$9.55 (3.53%)
$275
9 days ago
(07-Jul-2026)
6/7 (85.71%)
$13.03 (4.88%)
141
Buy Since 20-Apr-2020
$355
$94.25 (36.15%)
$243
1 months 27 days ago
(19-May-2026)
18/19 (94.74%)
$117.02 (49.17%)
855
Buy Since 07-Jan-2025
$345
$84.25 (32.31%)
$342
2 months 5 days ago
(11-May-2026)
3/6 (50%)
$106.33 (44.55%)
138
Buy Since 11-Mar-2021
$326
$65.25 (25.02%)
$330
2 months 8 days ago
(08-May-2026)
10/16 (62.5%)
$87.34 (36.60%)
933
Buy Since 16-Mar-2022
$292
$31.25 (11.98%)
$260
3 months ago
(16-Apr-2026)
18/19 (94.74%)
$49.05 (20.19%)
322
What Year was the first public recommendation made by Maxwell Skor?
